< Terug naar vorige pagina


Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1

Tijdschriftbijdrage - Tijdschriftartikel

The inhibitor-of-apoptosis family member survivin has been reported to inhibit apoptosis and regulate mitosis and cytokinesis. In multiple myeloma, survivin has been described to be involved in downstream sequelae of various therapeutic agents. We assessed 1093 samples from previously untreated patients, including two independent cohorts of 392 and 701 patients, respectively. Survivin expression was associated with cell proliferation, adverse prognostic markers, and inferior event-free and overall survival, supporting the evaluation of survivin as a therapeutic target in myeloma. The small molecule suppressant of survivin--YM155--is in clinical development for the treatment of solid tumors. YM155 potently inhibited proliferation and induced apoptosis in primary myeloma cells and cell lines. Gene expression and protein profiling revealed the critical roles of IL6/STAT3-signaling and the unfolded protein response in the efficacy of YM155. Both pathways converged to down regulate anti-apoptotic Mcl-1 in myeloma cells. Conversely, growth inhibition and apoptotic cell death by YM155 was rescued by ectopic expression of Mcl-1 but not survivin, identifying Mcl-1 as the pivotal downstream target of YM155 in multiple myeloma. Mcl-1 expression was likewise associated with adverse prognostic markers, and inferior survival. Our results strongly support the clinical evaluation of YM155 in patients with multiple myeloma.

Tijdschrift: Oncotarget
ISSN: 1949-2553
Issue: 21
Volume: 5
Pagina's: 10237-10250
Trefwoorden:Antineoplastic Agents/pharmacology, Apoptosis/drug effects, Cell Growth Processes/drug effects, Cell Line, Tumor, Cohort Studies, Down-Regulation, Gene Expression Regulation, Neoplastic/drug effects, Humans, Imidazoles/pharmacology, Inhibitor of Apoptosis Proteins/genetics, Interleukin-6/metabolism, Multiple Myeloma/diagnosis, Myeloid Cell Leukemia Sequence 1 Protein/genetics, Naphthoquinones/pharmacology, Prognosis, STAT3 Transcription Factor/metabolism, Survival Analysis, Survivin, Transcriptome, Unfolded Protein Response/drug effects